长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000661 长春高新

已收盘 12-15 15:00:00

{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":92.06,"timestamp":1765782222000,"preClose":93.65,"halted":0,"volume":6143856,"delay":0,"changeRate":-0.017,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":-1.59,"latestTime":"12-15 15:00:00","open":93.65,"high":93.65,"low":91.72,"amount":568000000,"amplitude":0.0206,"askPrice":92.07,"askSize":80,"bidPrice":92.06,"bidSize":61,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":93.65,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":103.02,"lowLimit":84.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":39.157805,"roe":"5.03%","epsLYR":6.42,"committee":0.151741,"marketValue":37555000000,"turnoverRate":0.0154,"status":1,"floatMarketCap":36789000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"1141150875","title":"长春高新宣布子公司与Yarrow Bioscience签署Gensci098注射剂项目许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1141150875","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141150875?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:47","pubTimestamp":1765802835,"startTime":"0","endTime":"0","summary":"长春高新宣布其子公司已与Yarrow Bioscience签署了涉及Gensci098注射剂项目的许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000661","BK0188","BK0028","BK0075","BK0057","BK0046"],"gpt_icon":0},{"id":"2591646738","title":"长春高新最新公告：下属公司签署GenSci098注射液项目独家许可协议可至多获得13.65亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646738","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591646738?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:39","pubTimestamp":1765802387,"startTime":"0","endTime":"0","summary":"长春高新公告称，下属公司上海赛增医疗科技有限公司与Yarrow Bioscience, Inc. 签订GenSci098注射液项目独家许可协议。根据协议，赛增医疗预计可获得1.2亿美元首付款及近期开发里程碑款项，并将有资格获得与特定研发、监管及商业化有关的里程碑付款。赛增医疗将有权就本次独家许可至多获得13.65亿美元里程碑付款，后续产品上市后并有权获得超过净销售额10%的销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500031815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0075","BK0188","BK0028","91272","BK0046","BK0057"],"gpt_icon":0},{"id":"2591614862","title":"长春高新：长效生长激素规格及医保价格说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614862?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789570,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：金培生长激素上市了哪几个剂量规格，这次医保谈判落地价格分别是多少？公司现在说一下这个不违规吧，我们投资人想了解。长春高新回复：您好，公司长效产品主要有54IU/9.0mg/1.0ml/瓶、27IU/4.5mg/0.5ml/瓶两个规格，2026年1月1日最新版医保目录正式执行后相关价格可正式查询，具体请以国家相关部门披露为准，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","91272","BK0188","BK0075","BK0239","BK0057","BK0028","000661"],"gpt_icon":0},{"id":"2591261106","title":"长春高新：系统性推进市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261106?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:00","pubTimestamp":1765789253,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月15日在投资者关系平台上答复投资者关心的问题。请问公司是否会重新评估回购用途，考虑将部分股份用于注销以提升每股价值？公司2026年是否有明确市值管理、费用控制及提升分红或注销式回购？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500020297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0239","91272","000661","BK0188","BK0046","BK0075"],"gpt_icon":0},{"id":"2589337793","title":"长春高新(000661.SZ)子公司两款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589337793?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:54","pubTimestamp":1765184075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，据国家医疗保障局及人力资源社会保障部发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)自主研发的金赛增(现通用名为“金培生长激素注射液”)、合作引进的美适亚(通用名为“醋酸甲地孕酮口服混悬液”)均被新纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91272","BK0188","BK0028","000661","BK0075","BK0046","BK0239","BK0057"],"gpt_icon":0},{"id":"2588919884","title":"长春高新：已回购股份将用于员工持股或股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2588919884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588919884?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:52","pubTimestamp":1764852748,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月03日在投资者关系平台上答复投资者关心的问题。前几年贵司进行了一次股权激励，但后来股价倒挂没有实施。这样不仅利于有贡献的员工也利于公司的发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0239","BK0188","BK0057","91272","BK0028","BK0046"],"gpt_icon":0},{"id":"2588439800","title":"长春高新：推进多元化转型升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2588439800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588439800?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:57","pubTimestamp":1764763033,"startTime":"0","endTime":"0","summary":"自信可以但也要变通长春高新回复：感谢您对公司的关注，在合规监管越来越严格的情况下，相关适应症的拓展将使公司能够更好的适应监管要求，更有利于产品的销售；公司后续也将继续努力发挥公司品牌、渠道、质量等优势，努力推动相关产品的销售推广工作；同时，公司近年来已经在积极推进多元化转型升级，前期在生长激素研发、销售推广阶段打下的基础，也将持续赋能新管线，推进公司持续形成‘优势共享、资源复用’的良性循环，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91272","BK0057","BK0075","BK0188","BK0239","BK0046","BK0028","000661"],"gpt_icon":0},{"id":"2588043807","title":"长春高新：提升资产使用效率及项目竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588043807?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:42","pubTimestamp":1764762127,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新12月03日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300034170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","BK0188","000661","91272","BK0028","BK0075","BK0239"],"gpt_icon":0},{"id":"2588048730","title":"长春高新：截至9月30日股东人数为104,055","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588048730?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:33","pubTimestamp":1764761584,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问截止到今天股东人数是多少？长春高新回复：您好，截至9月30日的股东人数为104,055，对于其他期间的股东人数请持续关注定期报告等，或根据公司法及公司章程等规定进行查询，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300033870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0075","91272","BK0057","BK0239","BK0046","BK0188"],"gpt_icon":0},{"id":"2586546243","title":"长春高新(000661.SZ)：GenSci142胶囊境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586546243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586546243?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:55","pubTimestamp":1764233713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci142胶囊注册临床试验申请获得批准。据悉，GenSci142胶囊是金赛药业开发的一款1类创新生物制品，拟用于细菌性阴道病的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000661","91272","BK0028","BK0046","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2585452675","title":"长春高新：相关工作具有不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452675?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:36","pubTimestamp":1763973379,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司总经理，在今年上半年不止一次说过,下半年会有产品bd出去。 然后到了下半年又改口说到2028年可能就会有bd出去,这算不算虚假指引误导投资者？长春高新回复：公司经营管理团队积极通过多种形式推进在研管线BD等工作，但相关工作具有不确定性，后续如有达到信息披露标准的情况公司将会及时履行披露义务，具体请关注公司未来相关公告等，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400018053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0057","BK0188","91272","BK0239","BK0028","BK0075"],"gpt_icon":0},{"id":"2585452884","title":"长春高新：未发现生长激素市场份额下降的科学合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452884?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973045,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：长效生长激素刚有一个对手上市公司就已经应对不暇。连续降价,同时市场份额也不断下降,明后两年还有至少5-7家长效要上市,届时合理推测公司生长激素业务营收将会降低到15亿以下,请问公司管理层可有应对策略？长春高新回复：公司会结合政策要求、行业及市场情况等合理制定产品价格和销售策略，另未发现您问题列示情况的科学合理性，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0075","BK0028","BK0239","BK0188","91272","000661","BK0057"],"gpt_icon":0},{"id":"2585855452","title":"长春高新：成功推出10余种新药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2585855452","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585855452?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:27","pubTimestamp":1763972834,"startTime":"0","endTime":"0","summary":"研发成果方面，自2021年以来，公司立足于差异化创新，在内分泌及代谢疾病、女性健康、免疫及呼吸系统疾病、肿瘤、疫苗及中成药领域建立了多元化产品组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0239","BK0028","BK0046","91272","BK0188","000661"],"gpt_icon":0},{"id":"2585540594","title":"生长激素难助业绩长高！昔日“东北药茅”欲借港股翻盘？","url":"https://stock-news.laohu8.com/highlight/detail?id=2585540594","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585540594?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:21","pubTimestamp":1763972460,"startTime":"0","endTime":"0","summary":"编者按：拆解企业招股、估值、上市表现，以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划，深度探寻每一次资本浪潮背后的机遇与逻辑，敬请关注。投资时间 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251124/c672688967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0188","000661","688276","BK0028","BK0046","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2584803130","title":"长春高新（000661）披露控股股东股权结构发生变更，11月20日股价下跌0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584803130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584803130?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:16","pubTimestamp":1763648186,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，其控股股东长春超达投资集团有限公司的股权结构发生变更。根据公告内容，经长春新区国有资产监督管理局决定，龙翔投资控股集团有限公司将其持有的超达集团100%股权中的19%无偿划转至长春新区产业投资集团有限公司。本次变更完成后，龙翔集团持有超达集团81%股份，新区产投持有19%股份，实际控制人均为长春新区国有资产监督管理局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0239","BK0028","BK0046","91272","BK0188","000661"],"gpt_icon":0},{"id":"2584910307","title":"长春高新：相关适应症拓展将更好适应监管要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910307","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584910307?lang=zh_cn&edition=full","pubTime":"2025-11-19 18:42","pubTimestamp":1763548942,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问：生长激素花怎么多钱做适用症，价值体系没有看到，跟竞品单适用症都还是再一个竞争位置上，想问下公司目前有没有采取办法，突出花怎么多再适用症的价值上。长春高新回复：感谢您对公司的关注，在合规监管越来越严格的情况下，相关适应症的拓展将使公司能够更好的适应监管要求，更有利于产品的销售；同时公司后续也将继续努力发挥公司品牌、渠道、质量等优势，努力推动相关产品的销售推广工作，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900032566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0057","BK0188","BK0028","BK0075","91272","BK0046","000661"],"gpt_icon":0},{"id":"2584914541","title":"长春高新：暂无金蓓欣海外临床安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2584914541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584914541?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:27","pubTimestamp":1763544429,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问：金蓓欣效果非常好，请问公司有将其在国外上市的打算吗?长春高新回复：您好，感谢您对公司相关产品的认可，目前相关产品公司主要侧重于加快推进国内市场的销售推广，暂无进行海外临床的安排；对于一些认可国内药品审核程序的国家地区，公司会根据相关产品及地区情况研究海外销售安排，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900027665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0028","91272","BK0057","BK0075","BK0188","BK0046"],"gpt_icon":0},{"id":"2584591486","title":"长春高新：美适亚销售投入具商业价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2584591486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584591486?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:21","pubTimestamp":1763544085,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，医药行业新产品一般需要一定的市场培育期，公司认为美适亚产品相关适应症对应的患者人群存在较大的未被满足的需求，公司相关投入是有意义的；另，对于销售费用，员工薪酬只占其中的一小部分，具体细分情况请以公司定期报告-财务报告-销售费用相关内容为准，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900027352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","91272","BK0188","BK0075","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2584856911","title":"长春高新：系统性推进市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2584856911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584856911?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:57","pubTimestamp":1763542649,"startTime":"0","endTime":"0","summary":"我相信广大股东和董事会愿意为做好市值管理而给予董秘更高的待遇，希望董秘能够积极对外路演，同时把公众号运用起来，加快对外更新研发进展的频次，推动公司重新坐上千亿市值的宝座。另外请公司董秘说明未来一年的市值管理工作规划？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900026390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","91272","BK0075","000661","BK0188","BK0046","BK0057","BK0239"],"gpt_icon":0},{"id":"2584911855","title":"长春高新：生产成本较同行更具优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2584911855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584911855?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:54","pubTimestamp":1763542475,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新11月19日在投资者关系平台上答复投资者关心的问题。想具体的知道，公司把大量资金砸向新品开发的同时如何维护好这个基本盘不被别人抄了家长春高新回复：您好，基于公司相关产品的规模效应、核心原材料自产等情况，公司相关产品生产成本较同行业公司更具有优势，同时随着技术、工艺、设备升级，公司将持续优化生产成本等，具体需披露的生产成本等情况请关注公司定期报告等公告中列示的相关内容，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900026323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","000661","BK0028","91272","BK0057","BK0075","BK0239","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765809958535,"stockEarnings":[{"period":"1week","weight":-0.061},{"period":"1month","weight":-0.0946},{"period":"3month","weight":-0.255},{"period":"6month","weight":-0.1328},{"period":"1year","weight":-0.1109},{"period":"ytd","weight":-0.0355}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":"　　长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}